Related Experiment Video
Updated: May 29, 2025
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
[Combination therapy for the treatment of hypercholesterolemia: primary and secondary prevention]
Stefania Angela Di Fusco1, Furio Colivicchi1
1U.O.C. Cardiologia Clinica e Riabilitativa, Presidio Ospedaliero San Filippo Neri - ASL Roma 1, Roma.
Insights
Combining lipid-lowering agents like statins and ezetimibe is effective for managing atherosclerotic cardiovascular disease. This approach improves low-density lipoprotein cholesterol (LDL-C) reduction and patient adherence compared to high-dose statin monotherapy.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Background:
- Low-density lipoprotein cholesterol (LDL-C) reduction is critical for managing atherosclerotic cardiovascular diseases (ASCVD).
- Combination therapy offers improved LDL-C lowering and adherence compared to high-dose statin monotherapy.
Purpose of the Study:
- To review therapeutic targets for ASCVD prevention.
- To analyze evidence for statin/ezetimibe combination in primary and secondary prevention.
- To discuss the impact of rosuvastatin/ezetimibe on LDL-C, plaques, and clinical events.
Main Methods:
- Literature review of clinical guidelines and studies.
- Analysis of evidence on lipid-lowering agent efficacy and safety.
- Focus on statin/ezetimibe combination therapy.
Main Results:
- Combination therapy is an effective and safe strategy for LDL-C reduction.
- Improved patient adherence observed with combination therapy versus high-dose statins.
- Data on rosuvastatin/ezetimibe in secondary prevention regarding plaque stabilization and clinical outcomes.
Conclusions:
- Statin/ezetimibe combination therapy is a valuable strategy in ASCVD management.
- This combination enhances LDL-C reduction and patient adherence.
- Further data supports its role in secondary prevention, impacting atherosclerotic plaques and clinical events.
Abstract:
The reduction of low-density lipoprotein cholesterol (LDL-C) is the cornerstone of atherosclerotic cardiovascular diseases management, both in primary and secondary prevention. The use of more lipid-lowering agents represents an effective and safe option to reduce LDL-C with the advantage of a better adherence to treatment compared to the use of higher statin dosages as monotherapy. This review focuses on therapeutic targets as recommended in different clinical settings in primary and secondary prevention, and analyzes evidence on the statin/ezetimibe combination use in primary prevention. Furthermore, we discuss the impact of rosuvastain/ezetimibe combination in secondary prevention and report available data on LDL-C reduction and on the effects on atherosclerotic plaques and clinical events.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...